drugset / Trial / NCT05179668
SGLT2 Inhibition in Hemodialysis
RandomizedParallel-groupTriple-blindTreatment
Summary
Dapagliflozin will be compared with placebo to evaluate its effects on cardiac structure and safety in patients with kidney failure receiving maintenance hemodialysis.
Timeline
- Start
- 2022-10-01
- Primary completion
- 2025-07-11
- Completion
- 2026-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dapagliflozin | Small molecule | 10 mg | Oral |